Journal of Neurology and Neuroscience

  • ISSN: 2171-6625
  • Journal h-index: 18
  • Journal CiteScore: 4.35
  • Journal Impact Factor: 3.75
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • The Global Impact Factor (GIF)
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Scientific Journal Impact Factor (SJIF)
  • Euro Pub
  • Google Scholar
  • Secret Search Engine Labs
Share This Page

Short Communication - (2023) Volume 14, Issue 3

Emerging therapeutic approaches for neurological disorders: Targeting neurotransmitter systems

Maria Lopez*
Department of Neuropharmacology, University of Cambridge, Cambridge, UK
*Correspondence: Maria Lopez, Department of Neuropharmacology, University of Cambridge, Cambridge, UK, Email:

Received: 29-May-2023, Manuscript No. ipjnn-23-13911; Editor assigned: 31-May-2023, Pre QC No. P-13911; Reviewed: 14-Jun-2023, QC No. Q-13911; Revised: 20-Jun-2023, Manuscript No. R-13911; Published: 28-Jun-2023


Neurological disorders, including Parkinson's disease, Alzheimer's disease, and epilepsy, pose significant challenges to individuals and society as a whole. Traditional treatment approaches often focus on symptomatic relief rather than addressing the underlying causes. However, recent advances in our understanding of neurotransmitter systems have opened new avenues for developing targeted therapeutic approaches. This review explores the emerging therapeutic approaches for neurological disorders by targeting neurotransmitter systems. We discuss the roles of key neurotransmitters, such as dopamine, acetylcholine, and Gamma-Aminobutyric Acid (GABA), in neurological function and their dysregulation in various disorders. Furthermore, we delve into innovative strategies, including receptor modulation, enzyme inhibition, and gene therapy, aimed at restoring neurotransmitter balance and improving clinical outcomes. Understanding and harnessing the potential of these emerging therapeutic approaches offer promising prospects for addressing the root causes of neurological disorders and enhancing the quality of life for affected individuals [1].


Neurotransmitters are essential signaling molecules in the central nervous system, mediating communication between neurons and regulating various physiological processes. Dysregulation of neurotransmitter systems can lead to neurological disorders, as seen in the depletion of dopamine in Parkinson's disease or the imbalance of acetylcholine in Alzheimer's disease [2]. Emerging therapeutic approaches for neurological disorders aim to target specific neurotransmitter systems to restore their balance and alleviate symptoms. Strategies include receptor modulation, where drugs can selectively activate or inhibit specific receptors to enhance or suppress neurotransmission. For example, dopamine receptor agonists are used to compensate for dopamine loss in Parkinson's disease, providing symptomatic relief and improving motor function [3].

Enzyme inhibition is another approach to modify neurotransmitter levels. Inhibitors can be employed to block enzymes responsible for the breakdown or reuptake of neurotransmitters, thus prolonging their availability in the synaptic cleft. This strategy has been effective in increasing acetylcholine levels in Alzheimer's disease, slowing down cognitive decline [4]. Gene therapy, a promising avenue,

involves introducing genes into specific cells to restore proper neurotransmitter synthesis or release. This approach has shown potential in neurodegenerative disorders such as Huntington's disease, where gene delivery can enhance the production of GABA, reducing motor symptoms and preventing neuronal degeneration.

Additionally, emerging techniques such as Deep Brain Stimulation (DBS) and Transcranial Magnetic Stimulation (TMS) provide non-pharmacological methods to modulate neurotransmitter systems. DBS involves the implantation of electrodes in specific brain regions to electrically stimulate neural circuits, offering therapeutic benefits for conditions like Parkinson's disease and epilepsy. TMS, on the other hand, utilizes magnetic fields to non-invasively stimulate targeted brain regions, showing promise in treating depression and other psychiatric disorders [5].


Emerging therapeutic approaches targeting neurotransmitter systems present exciting prospects for the treatment of neurological disorders. Understanding the dysregulation of specific neurotransmitters, such as dopamine, acetylcholine, and GABA, has paved the way for innovative interventions aimed at restoring balance and function. Advances in receptor modulation, enzyme inhibition, gene therapy, and neuromodulation techniques offer diverse strategies for addressing the root causes of neurological disorders. These approaches hold potential for improving symptoms, slowing disease progression, and enhancing the quality of life for affected individuals.

Further research is needed to refine and optimize these therapeutic approaches, ensuring their safety, efficacy, and long-term effects. Integration of advanced technologies, such as precision medicine and personalized treatment approaches, will enable tailored interventions for individuals with specific neurotransmitter dysregulations. By targeting neurotransmitter systems and restoring their balance, emerging therapeutic approaches provide hope for more effective treatments that address the underlying causes of neurological disorders. Continued advancements in our understanding of neurotransmitter function, combined with innovative therapeutic strategies, will pave the way for better outcomes and improved quality of life for individuals living with neurological disorders.



Conflict of Interest



  1. Kawano H, Kimura-Kuroda J, Komuta Y, et al. Role of the lesion scar in the response to damage and repair of the central nervous system. Cell Tissue Res. 2012;349(1):169-180.
  2. Google Scholar, Crossref, Indexed at

  3. Emery E, Aldana P, Bunge MB, et al. Apoptosis after traumatic human spinal cord injury. J Neurosurg. 1998;89(6):911-920.
  4. Google Scholar, Crossref, Indexed at

  5. Norenberg MD, Smith J, Marcillo A. The pathology of human spinal cord injury: Defining the problems. J Neurotrauma. 2004;21(4):429-440.
  6. Google Scholar, Crossref, Indexed at

  7. Zai LJ, Wrathall JR. Cell proliferation and replacement following contusive spinal cord injury. Glia. 2005;50(3):247-257.
  8. Google Scholar, Crossref, Indexed at

  9. Lau LW, Cua R, Keough MB, et al. Pathophysiology of the brain extracellular matrix: A new target for remyelination. Nat Revs Neurosci. 2013;14(10):722-729.
  10. Google Scholar, Crossref, Indexed at